APA

Bakker J., Grover R., McLuckie A., Holzapfel L., Andersson J., Lodato R., Watson D., Grossman S., Donaldson J. & Takala J. (20040212). Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). : Critical care medicine.

Chicago

Bakker Jan, Grover Robert, McLuckie Angela, Holzapfel Laurent, Andersson Jan, Lodato Robert, Watson David, Grossman Steven, Donaldson Jill and Takala Jukka. 20040212. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). : Critical care medicine.

Harvard

Bakker J., Grover R., McLuckie A., Holzapfel L., Andersson J., Lodato R., Watson D., Grossman S., Donaldson J. and Takala J. (20040212). Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). : Critical care medicine.

MLA

Bakker Jan, Grover Robert, McLuckie Angela, Holzapfel Laurent, Andersson Jan, Lodato Robert, Watson David, Grossman Steven, Donaldson Jill and Takala Jukka. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). : Critical care medicine. 20040212.